Fonnation of leukotriene 8 4
Leukotriene B 4 (5 [S], 12 [R]-dihydroxy-6, 14-cis-8, lO-trans-eicosatetraenoic acid) is formed following an initial lipoxygenase attack at position C5 on the arachidonic acid molecule (Figure 1 ). Molecular oxygen is inserted to produce the unstable intermediate, 5hydroperoxy-eicosatetraenoic acid . This compound may be converted either to the corresponding monohydroxy fatty acid, via the glutathione peroxidase system, or to another unstable intermediate leukotriene A 4 (LTA 4 ) . The term leukotriene was proposed by Samuelsson for these compounds to indicate that they were derived from leukocytes and that they possessed a conjugated triene structure. The triene structure gives these compounds their characteristic ultraviolet spectrum. LTA 4 is a key intermediate in the formation of the remaining leukotrienes and has an unstable epoxide bridge across C5 and C6. Conjugation of glutathione with LTA 4 by a glutathione S-transferase enzyme leads to the production of leukotriene C 4 (LTC 4 ) . LTC 4 can lose its glutamic acid residue on exposure to gammaglutamyl transpeptidase to produce leukotriene D 4 (LTD 4 ) . LTD 4 can then in tum lose the glycine residue to produce leukotriene E 4 ' (LTE 4 ) . LTC 4 , LTD 4 and LTE 4 collectively account for the activity known as slow-reacting substance of anaphylaxis (SRS-A) and may be important mediators of hypersensitivity diseases such as asthma (for a review on the chemistry of SRS-A see Piper 1981) . Enzymatic hydrolysis of LTA 4 leads to the formation of a 5, 12-dihydroxy fatty acid, LTB 4 • This may then be metabolized by leukocytes to various trihydroxy fatty acids which have less biological activity than LTB 4 • Non-enzymatic The structure of LTB 4 was first determined following its purification from supernatants obtained from PMNs stimulated with the calcium ionophore A23187 (Borgeat & Samuelsson 1979a, b) . Exposure of PMNs to the synthetic peptide F-met-Ieu-phe (FMLP) or to arachidonic acid also results in the release of the leukotriene (Bray et al. 1981a) , and it appears likely that exposure of PMNs to a wide variety of stimuli results in the synthesis of LTB 4 • LTB 4 is produced by other leukocyte preparations including human eosinophils and both resting and elicited rat peritoneal macrophages (Doig & Ford-Hutchinson 1980) . It has also been detected in perfusates from isolated guinea-pig lungs challenged with antigen (Morris et al. 1979) . In vivo LTB 4 has been shown to be present in synovial fluid from patients with either non-inflammatory arthropathies or rheumatoid arthritis (Klickstein et al. 1980) . It has also been found in rat peritoneal fluid 5 minutes after anaphylactic challenge (Bray et al. 1981a) and is present in the sputum of patients with cystic fibrosis (Cromwell et al. 1981 ) .
Properties of leukotriene 8 4 LTB 4 was first identified as a potent mediator of leukocyte function by , who demonstrated that it was a potent chemokinetic and aggregating agent for neutrophils. This was subsequently confirmed by other workers (Palmer et al. 1980) and.it was shown also to be a potent chemotactic agent and an inducer of enzyme release from PMNs pretreated with cytochalasin B (Goetzl & Pickett 1980) . The chemotactic and chemokinetic activities of LTB 4 are comparable to those seen for the complement-derived peptide C5a and the synthetic peptide FMLP (Bray et al. 1981a , Goetzl & Pickett 1981 . The effects of LTB 4 on lysosomal enzyme release, however, are qualitatively the same but quantitatively less than those seen with other chemotactic agents (Goetzl & Pickett 1980) . LTB 4 also stimulates the movement of other leukocyte populations in vitro, including guinea-pig eosinophils, rat macrophages and human monocytes . The compound has no effect on platelet aggregation or lymphocyte transformation and does not contract the guinea-pig ileum.
The actions of LTB 4 in vivo have also been investigated. In the skin of the rabbit, rat and guinea-pig, in the presence of a vasodilator such as PGE z , the leukotriene produces marked increases in vascular permeability (Bray et al. 1981b ). This effect is dependent upon the presence of neutrophils and appears to result from some undefined interaction of PMNs with vascular endothelial cells (Wedmore & Williams 1981) . Similar effects are seen with other chemotactic factors such as C5a and FMLP. These changes in vascular permeability have been correlated with the accumulation of PMNs in rabbit skin (Bray et al. 1981c) . PMN accumulation in vivo has also been observed following injection of LTB 4 into the rabbit eye (Bhattacherjee et al. 1981 ) and the guinea-pig peritoneum . PMN accumulation in man has been observed following application of skin chambers containing solutions of LTB 4 over skin abrasions on the human forearm (Bray et -al. 1981 c) .
Conclusion
These results demonstrate that LTB 4 is a potent mediator of leukocyte movement both in vitro and in vivo. Its presence in rheumatoid synovial fluid shows that it may be an important mediator of inflammation. It has similar biological properties to the complement-derived peptide C5a but differs from this compound in that it may be produced by the cell upon which it acts. This suggests that LTB 4 may have an intracellular role as a modulator of the action of other stimulators of neutrophil function. There are no specific inhibitors of LTB 4 production and, unlike the prostaglandins, the biosynthesis of leukotrienes is probably unaffected by therapeutic concentrations of non-steroidal anti-inflammatory drugs. The production of LTB 4 may, however, be inhibited, at least in part, by steroids through induction of a phospholipase inhibitor. The lack of specific inhibitors of leukotriene biosynthesis makes it difficult to assess their true role in inflammatory diseases in man, but it would be hoped that if such inhibitors became available they would offer a novel therapeutic approach to the treatment of inflammation.
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